Lv6
3010 积分 2020-10-15 加入
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
4天前
已完结
Real-world experience with pacritinib for patients with myelofibrosis refractory to ruxolitinib: a report of three cases
2个月前
已完结
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
2个月前
已完结
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging
3个月前
已完结
Comparison of the enzymatic and cellular profiles of clinical JAK inhibitors for the treatment of myelofibrosis
3个月前
已完结
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study
3个月前
已完结
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
3个月前
已完结
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
3个月前
已完结
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
3个月前
已完结
皖公网安备34019202002308
